The film focuses on embalmers and funeral directors who claim to be coming forward to share their concerns over “unusual blood clots” found during prepared for burial, and Ryan Cole, MD, a promoter of false claims about the COVID vaccines and cancer. In the end, it is a combination of lies, theatrics, and scare tactics that rehash already-debunked claims.

Some of the key findings of this meta-analysis of antiviral therapy in the outpatient setting include: (treatment vs no-treatment) Probable reduction of hospitalization with Nirmatrelvir–ritonavir and casirivimab–imdevimab (1% vs 6%) Probable reduction in all-cause mortality with Nirmatrelvir–ritonavir (0% vs 1%) Probable improved recovery with regdanvimab (87% vs 72%) Four-day reduction in time to recovery with casirivimab-imdevimab Possible reduction in recovery rates with hydroxychloroquine

In this trial involving 29 healthcare facilities in 4 countries from May 2020 through April 2022, PCR-confirmed COVID infection occurred in approximately 10.5% of the mask group versus approximately 9.3% of the N95 group.

In this cohort study of insurance data over an 18-year period covering more than 15,000 pregnancies that involved methadone or buprenoprine use, buprenorphine in pregnancy was associated with a lower risk of adverse neonatal outcomes versus methadone use. However, the risk of adverse maternal outcomes was similar.

Trial participants were instructed on imagery rehearsal therapy — rewriting their recurring nightmare to end on a positive note and then rehearsing that story. Next, targeted memory reactivation was used to link a sound to that positive version of the dream. Those in the study reduced their nightmares from an average of almost 3 per week, to just one every five weeks.

In a trial randomizing 372 participants to deferiprone or placebo, nigrostriatal iron content decreased more in the deferiprone group than in the placebo group, but that didn’t correlate to a clinical benefit. Instead, 22% of those on the chelator required initiation of dopaminergic therapy versus 2.7% of those in the placebo group.